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ABSTRACT

y-Aminobutyric Acid Inhibits Synergistic Interleukin-6 Release but not
Transcriptional Activation in Astrocytoma
By
Joseph Dana Roach Jr.
Dr. Bryan L. Spangelo, Examination Committee Chair
Professor of Chemistry
University of Nevada, Las Vegas

A decline in the inhibitory neurotransmitter y-aminobutyric acid (GABA) may
enhance

cytokine

neuroinflammation.

release

in

Alzheimer’s

disease

(AD)

resulting

in

We investigated the GABA-mediated suppression of the

synergistic release of interleukin-6 (IL-6) due to interleukin 1-p (IL-1p ) and tumor
necrosis factor a (TNF-a) synergy. Our results indicate that p38 and nuclear
factor (NF)-kB are essential for the synergistic release of IL-6 by IL-ip and TNFa. Both IL-ip

and TNF-a stimulate p38 phosphorylation and each are able to

enhance the degradation of the NF-kB inhibitor, IxB-a, with no change in IxB-p.
Interestingly, co-treatments IL-ip and TNF-a induce a greater increase in IxB-a
degradation compared to either cytokine alone. In addition, co-treatment
increased IL-6 mRNA indicating synergy on a transcriptional level. In addition,
Western blot analysis revealed that co-treatments of IL-ip and TNF-a resulted in
an increase of IL-6 protein that can be reversed by GABA. Furthermore, co
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treatments of IL-ip and TNF-a resulted in activation of p38 and degradation of
k B -a at earlier time points compared to either cytokine alone. These data
suggests that IL-ip and TNF-a synergizes by accelerating p38 and NF-k B
activation, increasing IL-6 transcription. Although GABA suppressed the IL-ip
and TNF-a synergistic release of IL-6, it did not affect k B -a or kB-p
degradation, p38 phosphorylation or IL-6 transcription. Instead it appears that
GABA may inhibit IL-6 translation. We have demonstrated that this synergistic
release of IL-6 can be inhibited by GABA and its receptor agonists.

IV

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

TABLE OF CONTENTS
iii

ABSTRACT...........................

LIST OF FIGURES....................................................................................................... vil
ABBREVIATIONS....................................................................................................... viii
ACKNOWLEDGEMENTS............................................................................................ ix
CHAPTER 1 INTRODUCTION..................................................................................... 1
The biological foundation of the central nervous system....................................1
Biochemical features of Alzheimer disease......................................................... 3
7
Mitogen-activated protein kinases....................................................
Cytokines and their biological effects.................................................................... 8
Nuclear Factor-xB.................................................................................................. 10
y-Aminobutyric acid and inhibitory neuropeptide...............................................12
Hypothesis Statement............................................................................................13
CHAPTER 2 MATERIALS AND M ETHO DS............................................................14
Chemicals, reagents and equipment.................................................................. 14
C6 glioma cell culture............................................................................................16
Cytokine quantification via ELISA........................................................................16
Collection of cellular lysates..................................................................................17
RNA extraction and semi-quantitative RT-PCR analysis..................................18
SDS-PAGE Western blot analysis.......................................................................19
CHAPTER 3 RESULTS............................................................................................. 21
Time dependent release of IL-6 induced by TNF-a and IL -ip ........................ 21
GABA inhibition of the synergistic release of IL-6 induced by TNF-a and
IL -ip ........................................................................................................................21
Effects of GABA, muscimol, baclofen, TNF-a and IL-ip on IL-6 Release
22
TNF-a and IL-1 p effects on p38, IkB-o and Ik B-P in an extended time
course......................................................................................................................22
Effects of split number on cellular responses..................................................... 23
Effects of TNF-a and IL-ip on p38, Ik B-o and Ik B-P at 2-10 minutes
23
Effects of muscimol, baclofen, TNF-a and IL-ip on p38, Ik B-o and kB-p.... 24
Effects of TNF-a, IL-ip, Bay 11-7082 and GABA on kB -a degradation
24
Effects of low concentrations of TNF-a and IL-1 p on p38, kB -a and kB -p.. 25
Effects of low concentrations of TNF-a, IL-1 p and GABA on kB -a and

V

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Ik B-P........................................................................................................................25
Effects of TNF-a, IL-1 p and GABA on kB -a and GABA dose responses on
kB -a and k B - p ..................................................................................................... 26
Effects of TNF-a, IL-1 P and GABA on IL-6 transcription.................................. 26
Evaluation of total cellular content of IL-6.......................................................... 27
CHAPTER 4 DISCUSSION........................................................................................ 28
GABA inhibition of the synergistic release of IL-6 by TNF-a and IL -ip
29
Mechanism of the TNF-a and IL-ip synergisticstimulation of IL-6 release.. 29
Effects of GABA on the inhibition of IL-6 release induced by TNF-a and
IL-ip ......................................................................................................................31
REFERENCES............................................................................................................. 60
V ITA .............................................................................................................................. 67

VI

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

LIST OF FIGURES
Figure
Figure
Figure
Figure

1
2
3
4

Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22

Schematic of AD progression............................................................. 38
Structural projection of GABA............................................................. 39
Structural projections of muscimol and baclofen..............................40
GABA inhibition of IL-6 release caused by synergistic stimulation
of TNF-a and IL-13 .............................................................................. 41
Time dependent release of IL-6 by TNF-a and IL -ip .......................42
GABA inhibition of the synergistic release of IL-6 by TNF-a and
IL -ip ...................................................................................................... 43
Effects of GABA, muscimol, baclofen, TNF-a and IL-1 p on
IL-6 release........................................................................................... 44
TNF-a and IL-1 P effects on p38, kB -a and kB-p in an
extended time course..........................................................................45
Effects of split number on cellular responses................................... 46
Effects of TNF-a and IL-1 p on p38, kB -a and kB-P at 2 and
5 minutes...............................................................................................47
Effects of TNF-a and IL-1 p on p38, kB -a and kB-p at 5, 7.5 and
5 minutes...............................................................................................48
Effects of muscimol, baclofen, TNF-a and IL-1 p on p38, kB -a
and k B -p ...............................................................................................49
Structural projection of Bay 11 -7082.................................................. 50
Effects of TNF-a, IL-1 p, Bay 11 -7082 and GABA on
kB -a degradation................................................................................ 51
Effects of low concentrations TNF-a and IL-1 p on p38, kB -a
and k B -p ...............................................................................................52
Effects of low concentrations of TNF-a, IL-1 P and GABA on
kB -a and k B -p ....................................................................................53
Effects of TNF-a, IL-ip and GABA dose responses on kB -a
and k B -p ...............................................................................................54
Effects of TNF-a, IL-1 p and GABA on IL-6 transcription..................55
Relative expression levels of IL-6 transcript..................................... 56
Evaluation of total cellular IL-6 content.............................................. 57
GABA inhibition of IL-6 translation......................................................58
Proposed pathway of TNF-a and IL-1 p and GABA with relation
to IL-6 release....................................................................................... 59

VII

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ABBREVIATIONS
Ap - p-Amyloid
AD - Alzheimer’s Disease
APP - Amyloid Precursor Protein
p-ME - 2-mercaptoethanol
BSA - Bovine Serum Albumin
CNS - Central Nervous System
DMSG - Dimethyl Sulfoxide
ECL - Enhanced Chemiluminescence
EDTA - Ethylenediaminetetraacetic Acid
ELISA - Enzyme-Linked Immunosorbent Assay
ERK - Extracellular-Related Kinase
PBS - Fetal Bovine Serum
G3PDH - glyceraldehydes-3-phosphate dehydrogenase
GABA - y-Aminobutyric Acid
HEPES - 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid
HRP - Horseradish Peroxidase
Ik B - Inhibitor of k B
IKK - Ik B Kinase
IL - Interleukin
IL-1 i - IL-1 Inhibitor
IL-1 ra - IL-1 Receptor Antagonist
INF - Interferon
JNK - c-Jun-N-Terminal Kinase
kDa - Kilodalton
MAPK - Mitogen Activated Protein Kinase
NaCI - Sodium Chloride
NF-kB - Nuclear Factor-KB
NFT - Neurofibrillary Tangle
PAGE - Polyacrylamide Gel Electrophoresis
PBS - Phosphate-buffered Saline
PDL - Poly-D-Lysine
PHF - Paired Helical Filament
RPMI - Roswell Park Memorial Institute
SDS - Sodium Dodecyl Sulfate
TBST - Tris-Buffered Saline containing Tween
Tl - Tumor Necrosis Factor-a and Interleukin-1 p
TNF - Tumor Necrosis Factor
Tris - Tris-(hydroxylmethyl)-amino methane

VIII

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ACKNOWLEDGMENTS
There have been many people that were supportive in my pursual of higher
education.

First and foremost I would like to thank my immediate family and

friends for their support. I am especially grateful to have worked with my advisor
Dr. Bryan L. Spangelo. Your guidance, helpful analysis and interpretation of our
results were of a great help throughout my program. Additionally, the on-the-job
training that I received while working in your laboratory has given me great
experience.

I thank Dr. Spencer M. Steinberg, Dr. Ronald K. Gary and Dr.

Deborah K. Hoshizaki for being part of my committee and I would like to further
thank them for their participation, comments and help in bringing my thesis to
completion. I would also like to thank Dr. Francis “Monty” Hughes and his lab
technician Kaumudi Jonnalagadda for their time, efforts and patience for
assaying our RNA extracts. Finally, I would like to express much thanks and
appreciation to all my fellow lab-mates (Grant Aguinaldo, Christopher Mercado,
Lily Harizanova, Freidun Hadi, Subhasree Panchangam and Rachel Lewis) who
spent much time in the laboratory assisting me in my thesis research.
Financial support for this work was furnished by a grant (1R15NS05119801 A) from the National Institute of Neurological Disorders and Stroke at the
National Institutes of Health.

IX

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER 1

INTRODUCTION
The biological foundation of the central nervous system
In order to understand the effects of Alzheimer disease it is essential to
discuss the biological foundations of the central nervous system. The central
nervous system (CNS) consists of several cell types, including neurons
responsible for information processing and transmission. Neurons are aided by
supporting cells referred to glial cells. Nerve cells are secretory cells of varying
morphologies capable of information transfer thus generating electrochemical
impulses that travel the length reaching the synaptic cleft (Bowsher, 1988).
Nerve cells have the typical cellular features as well as other adaptations and
sacrifices to suit their unique roles. For example, neuronal cells can be relatively
large and long when compared to the morphology of other types of cells and form
vast networks to undertake information transfer. This large size and length is
essential in establishing communication networks with other cells in different
parts of the body.

Each neuron consists of the main cell body containing the

nucleus and NissI bodies which are large congregations of ribosomes (Bowsher,
1988), which are indicative of a higher than normal protein production.
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Another notable adaptation of neuronal cells is that they are less tolerant to
metabolic changes. For neurons, immediate cell death can occur if the oxygen
supply and

other substances are

diminished which

gives neurons the

characteristics of a simple metabolic profile (Bowsher, 1988). Another adaptation
is that neuronal cells consume energy at a higher rate than most other cells. To
meet this energy demand mitochondria take up nearly 66% of the entire volume
of a neuron (Bowsher, 1988). Yet another biological adaptation includes the
inability to replicate. The cell must sacrifice replication because of its size and
due branches that extend to varying distances and can range from a few
millimeters to over a meter in length (Bowsher, 1988). These dendritic trees are
essential in forming communication networks with other cells. In addition,
considerable time and resources are used to establish these connections that
can be lost if the cell were to undergo morphological changes during mitosis.
These branching bodies that extend from the neuronal main cellular body are
called dendrites and axons, which function to receive and transmit information,
respectively.
Dendrites receive information transmitted from other cells and conduct this
information towards the cell body and even to the axon or nerve fiber (Lawson,
2003). The ends of axons transmit and communicate to other cells (Lawson,
2003). Along these axons are microtubule (referred to as neurofilaments or
neurotubules) networks which extend to the terminals where neurotransmission
occurs (Bowsher, 1988). It is along these tubules that the phenomenon known as
axonal transport occurs, which is the active movement of neurotransmitters
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and/or their precursors along the axon in either direction (Bowsher, 1988). One
can think of these filaments as a highway for substances to be shuttled to and
from the axonal terminal, referred to as the bouton (button).
It is at the bouton where neurotransmission occurs through direct contact to
another cell body or to the dendrites of another cell (Bowsher, 1988). Electron
microscopy has shown that the bouton contain a large array of synaptic vesicles.
A nervous impulse travels along the axon and arrives at the bouton, resulting in
the release of neurotransmitters from the vesicles into the synaptic cleft
(Bowsher, 1988).

Biochemical features of Alzheimer disease
Alzheimer disease (AD) is a debilitating disease that affects the CNS. It was
first described by the German physician Alois Alzheimer in 1907 (Alzheimer,
1907) and despite the fact that researchers have had approximately one hundred
years to study this disease the cause is still unknown (Griffin, 2006) and no cures
have been developed. It is the most common form of dementia in the elderly. In
the U.S. alone AD to affects 4.5 million people and this is expected to increase to
13.2 million by 2050 (Herbert et al., 2003). In addition it has been estimated that
24.3 million people worldwide are affected by AD and this number is expected to
double every 20 years as life expectancy increases (Ferri et al., 2005). On the
biological level there are three features that define Alzheimer pathology. These
are [1] senile plaque formation; [2] neurofibrillary tangles or paired helical
filaments (PHF) first observed and characterized by Dr. Alzheimer in 1907; and
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[3] inflammation processes which contribute to the deposition of amyloid plaques
that form senile plaques (Qiao et al., 2001).
The amyloid plaques (A|3), originate from the processing of amyloid precursor
protein (APP) (Kang et al., 1987). Though the exact function or purpose of APP
or amyloid plaques is unknown, there is much data demonstrating potential roles
for APP. APP has a structure similar to membrane bound proteins (Kang et al.,
1987), indicative of some unknown function localized to cell membranes.
Furthermore, APP is highly expressed in nen/e terminals and may be essential
for

synaptic

formation

during

brain

development,

neurogenesis

and

neuroregeneration (Loffler and Huber, 1982 Chen et al., 2006, and Selkoe et al.,
1988). It is interesting to note that APP is up-regulated after head injury
(Gentlemen et al., 1993) and that APP is also deposited in aged Down syndrome
patients (trisomy-21); (Kang et al., 1987). Furthermore, it is also interesting to
note that the APP gene is located on chromosome 21 (Selkoe et al., 1988) and
that individuals affected with trisomy-21 have an earlier onset of brain growth
arrest, brain atrophy and the development of AD (Wisniewski et al., 1985). Using
trisomy-21 as a model, these observations suggests that up-regulation of APP
expression and processing can lead to the progression of AD.
The formation of amyloid plaques occurs through the processing of APP
fragments which are cleaved by a family of enzymes known as secretases . APP
processing results in the formation of P-amyloid (Ap) peptide fragments of ~ 3943 amino acid residues in length (Buxbaum et al., 1998, Cintron et al., 1994 and
Selkoe et al., 1996), each of which are found in amyloid plaque deposits in AD
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patients. In addition, missense mutations occur more frequently in the PAPP
gene of aged individuals resulting in the formation of extremely hydrophobic,
amyloidogenic and insoluble fragments (Cintron et al., 1994) which can further
exacerbate AD. These Ap fragments are proposed to be the underlying force that
ultimately initiates and drives AD development and progression (Hardy and
Higgins 1992).
This idea that Ap plaque formation is the causative force of AD has become
known as the amyloid cascade hypothesis (Hardy and Higgins, 1992).

This

hypothesis is widely acknowledged by mainstream AD researchers but is not
entirely accepted. For instance, it has been reported that there is a little or no
correlation between Ap plaque deposition and neurological dysfunction (Terry et
al., 1999-2000 and Klein et al., 2001). Terry et al., argue that it is the loss of the
synaptic terminals, rather than amyloid plaque deposition, which leads to the
development and progression of dementia. Those who do not agree with the
amyloid cascade hypothesis are few as there are over 5000 publications (Klein et
al., 2001) that support the hypothesis.
The second hallmark feature of AD is neurofibrillary tangles. Along the
lengths of the axons are microtubule fibers forming the backbone of the
axoplasmic transport system. These tubules serve as the internal support
structures transporting nutrients, vesicles, mitochondria, and other substrates
from the cell body to the ends of the axon and back (Griffin, 2006). A low
molecular weight protein known as tau is an integral component of microtubules
and can bind directly to the microtubule fiber promoting microtubule assembly
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(Avila 2006 Caceres et al., 1990 and Drubin et al., 1986). In AD, tau can become
hyper-phosphorylated allowing it to bind together and form tangles (Braak et al.,
1994) which have become known as paired helical filaments (PHFs) or
neurofibrillary tangles (NFTs). In addition, tau can impede axoplasmic transport
by competitive binding with the motor protein kinesin (Ebneth et al., 1998, Stamer
et al., 2002 and Trinczek et al., 1999). Another negative effect of tau hyper
phosphorylation is increased resistance to protein degradation (Poppek et al.,
2006), blocking axoplasmic transport and stabilizing PHFs.
The third feature of AD affected tissues is neuroinflammation. The microglia
which support neurons perceive amyloid plaques as foreign inclusions and
initiate a inflammatory response to remove these depositions by phagocytosis
(Dewitt et al., 1998). Initiation of the inflammatory response causes activation of
glial cells resulting in the release of pro-inflammatory cytokines such as IL-1 (3 and
SIOOP,

both of which have been associated with senile plaque formation

(Griffin, 2006). In addition, the release of inflammatory cytokines such as IL-ip
can up-regulate the expression and processing of APP leading to the deposition
of additional Ap fragments (Goldgaber et al., 1989 and Buxbaum et al., 1992). As
more APP is processed and Ap deposition increases, the microglia cells
eventually become overburdened in an attempt to remove plaques Storing these
fragments within the glia cell forces the cell to undergo lysis releasing the Ap
fragments that had been removed (Nagele et al., 2004). This system may self
propagate and amplify itself promoting the development and progression of AD
through an inflammatory response.

6
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IL-ip can lead to the phosphorylation of tau, which demonstrates a possible
relationship between IL-1 p, tau and the formation of neurofibrillary tangles. Li and
colleagues have reported that an increase in IL-ip correlated with the increased
phosphorylation of tau, which in turn decreased synaptophysin synthesis (Li et
al., 2003). They also reported that this effect can be blocked using the p38
inhibitor SB203580. They concluded that IL-ip signaling is mediated through p38
and is involved in tau phosphorylation, potentially leading to neurofibrillary
tangles (Figure 1).

Mitogen-activated protein kinases
The MAPK superfamily of kinases plays a major role in cellular signaling of
many different cellular processes. The MAPK family includes p38, extracellularsignal regulating kinase (ERK) and c-Jun N-terminal kinase (JNK). As shown
earlier, there are data supporting p38 in pro-inflammatory and stress responses
(Xia et al., 1995). Indirect evidence suggests that JNK may also play a role in
inflammation (Ip and Davis 1998 and Eynott et al., 2003). In contrast ERK has an
opposing role to that of JNK and p38 as it has been implicated in proliferation
and cell survival (Xia et al., 1995 and Rescigno et al., 1998).
Increased activities of p38 and JNK have been implicated in a rodent model
of AD (Savage et al., 2002) and post mortem analysis of human AD affected
brain tissues show activated c-Jun in neurofibrillary tangles implying a role for
JNK in AD (Pearson et al., 2006). It is interesting to note that Savage and
colleagues reported that the pro-inflammatory and stress responsive kinases p38
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and JNK were activated in a mouse model of AD whereas the developmental and
cell survival responsive ERK was not. From these data one can see further
evidence of the link between inflammation and AD and the potential involvement
of JNK. One could also argue that it is a combination of the pro-inflammatory and
stress response of p38 and JNK, respectively, in combination with the breakdown
of cell survival signaling of ERK that may allow the development and progression
of AD.

Cytokines and their biological effects
Cytokines are

proteins that play roles in differentiation,

proliferation,

inflammation, apoptosis, and induction of various proteins. Some cytokines
include interleukins (IL) and tumor necrosis factors (TNF) which carry out a broad
range of different functions in the cell. There are 33 known types of interleukins
designated interleukins, 1-33. Interleukin-1 p (IL-ip) is an important signaling
molecule in the pro-inflammatory response and has even been linked to AD
(Griffin, 2006).
The IL-1 subfamily of cytokines consists of three members: IL-1 a, IL-ip and
their negative feedback inhibitor IL-1 inhibitor (IL-li) which was later renamed to
IL-1 receptor antagonist (IL-1 Ra) (Dinarello, 1994). The precursor of IL-1 is a 35kilodalton (kDa) inactive peptide that must be processed to a 17 kDa active
polypeptide (Hazuda et al., 1990), which can be further altered via glycosylation.
This biologically active form binds to an IL-1 cell receptor initiating a proinflammatory response which activates the MAPK p38 and the transcription

8
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factor NF-k B (O’Niell, 2000). It is interesting to note that both p38 and NF-k B
have been associated with inflammatory response leading to the production and
secretion of IL-6 (Craig et al., 2000).
Another inflammatory cytokine which seems to play a role in AD is a family of
cytokines collectively referred to as tumor necrosis factors (TNF). The first TNF
was originally detected and observed over thirty years ago as a cell free cytotoxic
substance that induced apoptosis in tumor cells (Granger et al., 1969). Probably
the most characterized member of this family is TNF-a, first isolated by Carswell
and colleagues in 1975. In addition to inducing apoptosis, TNFs have been linked
to

inflammation,

responses

host

(Locksley

defenses,
et

al.,

autoimmunity

2001).

Although

and
TNF

other

immunological

triggers

beneficial

immunological responses, some of its effects are injurious to the host organism.
These detrimental effects include septic shock, cachexia and disease symptoms
(Tracey and Cerami 1994).
One can postulate that IL-ip and TNF-a may initiate an inflammatory
response through the activation of p38 and NF-kB, resulting in the production
and release of IL-6. Inflammation contributes to the processing and release of Ap
fragments (Goldgaber et al., 1989 and Buxbaum et al., 1992). Li and colleagues
reported that hyperphosphorylation is caused by p38. As for NF-k B, it is
proposed by O’Niell and colleagues that IL-ip activates p38, which in turn
activates NF-k B resulting in IL-6 transcription.

It has also been demonstrated

that activation of NF-k B can be reversed or inhibited by p38 inhibitor SKF (Kaur
et al., 2003). These data provides evidence that p38 inhibitors and potentially
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anti-inflammatory agents may reverse or infiibit inflammation which in turn may
alleviate some effects of AD.

Nuclear Factor-KB
Nuclear Factor-KB (NF-k B) is a transcription factor related to the Rel family
proteins (Ghosh et al., 1998) and exists in virtually all cell types. It is found in the
cytoplasm bound to an intrinsic inhibitor k B (Ik B) which prevents it from migrating
to the nucleus of the cell. The activity of NF-k B can be summed up in three
steps: [a] the inhibitor is phosphorylated by Ik B kinases (IKK); [b] ubiquination
marks it for degradation by proteosomes; and [c] released NF-k B translocates to
the nucleus and binds to the k B binding sites located in the promoters and
enhancers of many genes (Ghosh et al., 1998 and Abraham 2000). Some genes
that become activated include IL-1, IL-6, TNF-a, lymphotoxins and Interferons
(IFN). Furthermore these molecules can activate NF-k B (Kopp & Ghosh 1999)
allowing them to prime the inflammatory response or further exacerbate it. The
nature of the genes that are activated suggests that NF-k B is responsible for
initiating inflammation and plays a major role in immune response (Kopp &
Ghosh 1999).
The Ik B family of NF-k B inhibitors include kB-a, kB-p, Ik B-e and kB-y
(Ghosh et al., 1998). Though inhibitors, their effects vary depending on the
source of induction. For example, the first inhibitor to be characterized and
cloned was kB -a (Davis et al., 1991), which regulates NF-k B through a rapid
transient induction activity that also regulates itself in a negative feedback loop

10
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fashion where activated NF-k B causes the up-regulation of Ik B-o transcription
resulting in a bi-phasic activation period (Ghosh et al., 1998).
Where Ik B-o degradation leads to transient activation of NF-k B, degradation
of IkB-P leads to a persistent activation of NF-k B.

First purified, cloned and

characterized in 1995 its activity is much different than that of Ik B-o . The
inhibitory effect of Ik B-o relies on activated NF-k B to promote the transcription of
additional kB-a, where as activated NF-k B does not promote kB-p transcription.
The lack of this autoregulatory feedback loop leads to the persistent activation of
NF-kB (Thompson et al., 1995). One can speculate that the chronic inflammation
associated with AD may be a result of the persistent activation of NF-k B rather
than kB-p.
The last two members, kB-s and kB-y are the more recently discovered
members. Currently, Ik B-e and its functional relationship with NF-k B is still
unknown (Spiecker et al., 2000). All members of this family of inhibitors have
nuclear import and export functions and it has been postulated that each member
possesses this ability to varying degrees (Lee and Hannink 2002). There is
evidence suggesting that kB-e is less efficient in nuclear importing but is very
effective in NF-k B export from the nucleus (Lee and Hannink 2002, Tam and Sen
2001). Although nucleocytoplasmic shuttling abilities of kB-e has not been
examined in detail (Lee and Hannink 2002), this proposed function is gaining in
popularity. The last member, kB-y has been better characterized than kB-e.
There is much experimental data suggesting that kB-y inhibits NF-k B by

11
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attaching directly to nucleotides and thus preventing NF-k B from binding to DNA
(Bell et al., 1996). In addition, one can measure NF-k B activation indirectly by
measuring the degradation of the different IkB inhibitors.

y-Aminobutyric acid an inhibitory neurotransmitter
y-Aminobutyric Acid

(GABA)

is probably one of the most important

neurotransmitter in the CNS (Figure 2).

It is capable of mediating membrane

hyperpolarization or depolarization and is believed to be responsible for
developmental neuronal migration (Han et al., 2002) and rapidly inhibits synaptic
transmission (Kolaj et al., 2004 and Otis and Mody 1992). It has even been
shown that a GABA can inhibit the proinflammatory responses in T-cells (Tian et
al., 2004) and inhibit IL-ip induced IL-6 release (Spangelo et al., 2004).
Interestingly, individuals affected by AD have lower levels of GABA (Bareggi et
al., 1982); however, these findings are in constant debate as there are many
reports that support strong, little or no correlations of AD and GABA levels.
Receptors of GABA are functionally subdivided as GABAa or GABAb
receptors. The ionotropic GABAa receptor conducts chloride ions (Olsen and
Tobin 1990) and mediates fast inhibitory responses (Banks et al., 2002). GABAa
receptors are hetero-oligomeric protein structures that are composed of
pentamers each approximately 50 kDa (Olsen and Tobin 1990). In addition, it is
possible to selectively activate the GABAa receptor through the use of muscimol

(Figure 3; Murashita el al., 2007) or isoguvacine oxide (Frolund et al., 1995).
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In contrast to the ionotropic GABAa receptor the GABAb is a metabotropic G
protein coupled receptor (Kerr and Ong 2001). GABAa illicits fast inhibitory
responses, GABAb is responsible for slower inhibitory responses (Tamas et ai.,
2003 and Federici et al., 2005). Activation of GABAb receptors results in the
reduction of neurotransmission at excitatory and inhibitory synapses through an
increase in potassium conductance or a decrease in calcium currents (Kerr and
Ong 2001). One can selectively activate the GABAb receptor with the use of the
drug baclofen, structure shown in (Figure 3; Bartoletti et al., 2004).

Hypothesis Statement
Previous unpublished results demonstrated that GABA inhibits the release of
IL-6 due to TNF-a and IL-ip and these results were latter confirmed (Figure 4).
In addition, our preliminary results suggest that GABA inhibits IL-6 release and
may not be through a decrease in p38 activation or an inhibition of NF-kB
activation. In respect to the role played by inflammatory cytokines in AD, the work
presented in this thesis come from three separate but related hypothesis
statements. Hypothesis I: the synergistic effect of TNF-a and IL-ip arises from
an increase in IL-6 transcription. Hypothesis II: GABA, affects p38 or NF-kB
activation. Hypothesis III:

GABA may also inhibit the release of the pro-

inflammatory cytokine IL-6 by preventing its transcription induced by TNF-a and
IL-ip.
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CHAPTER 2

MATERIALS AND METHODS
Chemicals, reagents and equipment
y-Amino butyric acid (GABA), glycine, sodium chloride (NaCI), potassium
chloride, 4-(2-hydroxyethyl)-monosodium salt (HEPES), sodium dodecyl sulphate
(SDS), tris-(hydroxylmethyl)-amino-methane (Tris), tris-(hydroxylmethyl)-aminomethane

hydrochloride,

Tween-20,

dimethyl

sulfoxide

(DMSG),

2-

mercaptoethanol (P-ME), muscimol, baclofen and bromophenol blue were
obtained from Sigma-Aldrich (St. Louis, MO) and were of the highest grade
possible. High-molecular weight poly-D-lysine (PDL) hydrobromide was obtained
from BD Biosciences (Bedford, MA).

The pre-stained protein ladder was

obtained from Bio-Rad (Hercules, CA). Roswell Park Memorial Institute (RPMI)1640, PSN antibiotic mix, trypsin- ethylenediaminetetraacetic acid (EDTA), heatinactivated fetal bovine serum (FBS), phosphate-buffered saline (PBS pH 7.2),
PureLink Micro-to-Midi® total RNA purification system. Superscript II reverse
transcriptase and trypan blue were obtained from Invitrogen (Carlsbad, CA).
Methanol was obtained from EMD Chemicals (Gibbstown, NJ).
albumin

Bovine serum

(BSA) was obtained from Gemini Bioproducts (Woodland,

CA).

Recombinant rat IL-ip, TNF-a and rabbit anti-rat IL-6 antibody were obtained
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from

PeproTech

Inc.

(Rocky

Hill,

NJ).

phosphorylated

p38

(T180/Y182),

total

phosphorylated

JNK

(T183/Y185),

rabbit

Rabbit

p38,

anti-rat

total

anti-rat

JNK,

IL-6

kB -a,

kB-p,

mouse

anti-rat

antibody and the

biotinylated protein ladder was obtained from Cell Signaling (Danvers, MA).
Goat anti-rabbit and goat anti-mouse horseradish peroxidase (MRP) conjugated
secondary antibodies were obtained from KPL (Gaithersburg, MD). Bay 11-7082,
were obtained from EMD Biosciences (La Jolla, CA).

The rat 0 6 Glioma cell

lines were from the American Tissue Type Culture Collection (Rockville, MD).
Rat IL-6 sandwich enzyme-linked immunosorbent assay (ELISA) kits, M-PER®,
precasted 12% SDS- polyacrylamide gel electrophoresis (PAGE) gels, protease
and phosphatase inhibitor cocktails, and the microBCA® protein assay kit were
all obtained from Pierce Biotechnology (Rockford, IL).

Hoefer SE 260 mini

vertical gel electrophoresis unit, EPS 2A200 power supply, Hoefer TE 22 tank
transfer

unit,

Chemiluminescence

MultiTemp

III

(ECL)-Plus®

thermostatic
detection

reagent

circulator.
was

Enhanced

obtained

from

Amersham (Piscataway, NJ). Schleicher & Schuell Optitran® brand supported
0.45

pm

nitrocellulose membranes were obtained from

ISC

Bioexpress

(Kaysville, UT). Rabbit anti-rat IL-6 antibody was purchased from Cell Sciences
(Canton, MA). All small molecule inhibitors dissolved in sterile solvent, aliquoted
and stored at -20 °C until use. The final concentrations of DMSO never exceeded
0.1% of the final solution.
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C6 glioma cell culture
Rat C6 glioma cells were maintained in continuous culture in a humidified
atmosphere containing 95% air and 5% CO 2 in complete medium (RPMI1640/phenol red, medium containing 10% heat-inactivated PBS, 25 mM HEPES
pH 7.4, and PSN antibiotic mix). Cells were grown either in 25 cm^ or 75 cm^
area flasks. After 3-4 days in culture, cells were removed from the tissue culture
flasks with 2 mL (for the 25 cm^ area flask) or 6 mL (for 75 cm^ area flask) of
0.25% trypsin/ 0.05% EDTA in Hanks-buffered salt solution. Trypsin was
inactivated upon the addition of 8-24 mL of complete medium, cells were
centrifuged, pelleted, supernatant removed, and the pelleted cells resuspended
in complete medium.

Cell suspension densities and cellular viability were

determined via trypan blue exclusion. The cells were then placed (passed) back
into continuous culture (1.25 x 10® cells/25 cm^-area flask, BD Falcon) or were
seeded into tissue culture plastic-ware at the plating densities noted for
experiments. In all experiments presented, C6 glioma cells were used between
passages 5-35.

Cytokine quantification via ELISA
Rat C6 glioma cells were plated (1.0 x 10®/well) on 24 well plates using polyD-lysine (PDL) in complete medium and allowed to incubate 24 h to ensure
attachment. For the experiment, cells were washed twice with 2 mL serum-free
RPMI 1640 and incubated in serum-free RPMI-1640 in the absence or presence
of agents for the times and doses indicated for the experiments. IL-6 release was
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then assayed via rat IL-6 ELISA (Pierce Biotechnology) according to the
manufacturers’ instructions.

Collection of cellular protein lysates
Rat C6 glioma cells were plated (3.0 x 10®/dish) on PDL-coated 35 x 10 mm
dishes in complete medium, and allowed 24 h to attach. Following the
attachment period, the cells were washed twice with 2 mL serum-free RPMI-1640
and incubated in serum-free RPMI-1640 in the absence or presence of
stimulation agents for the times and doses indicated for the experiments. After
treatments cells were washed twice in 2 mL ice cold PBS, and scraped in 200 pL
of M-PER® (Pierce) containing both phosphatase and protease inhibitors (each
from Pierce). Protein-containing solutions were kept on ice and vortexed in 10
minute intervals for a total time of 30 minutes on ice.

Lysates were then

centrifuged at 14,000 x gf for 10 min at 4 °C and 175 pL of the supernatant was
recovered.

Protein concentrations were determined with Micro-BCA protein

assay kit (Pierce) using BSA as a standard and accordance to manufacturers’
instructions. Protein lysates were diluted by 20% using a 2X SDS-PAGE loading
buffer (10 % w/v SDS, 2 % v/v glycerol, 0.1 % w/v bromophenol blue, 0.5 M Tris
pH 6.8, and 5% v/v (3-ME), and boiled for 3 min. Protein lysates were
subsequently separated by SDS-PAGE Western blot analysis and samples were
stored at -80 °C for future analysis.
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RNA extraction and semi-quantitative RT-PCR
Rat C6 glioma cells were plated (3.0 x 10®/dish) on PDL-coated 35 x 10 mm
dishes in complete medium, and allowed 24 h to attach. Following the
attachment period, the cells were washed twice with 2 mL serum-free RPMI-1640
and incubated in serum-free RPMI-1640 in the absence or presence of
stimulation agents for the times and doses indicated for the experiments. After
treatments cells were washed twice in 2 mL ice cold PBS. Total RNA was then
extracted using the Invitrogen PureLink total RNA purification system.
To detect the presence of mRNA encoding IL-6 and glyceraldehydes-3phosphate dehydrogenase (G3PDH), semi-quantitative RT-PCR analyses were
performed as described by Elsawa et al., 2004 and Best et al., 1995. One pg of
total RNA was reverse transcribed using Superscript II reverse transcriptase
(Invitrogen), and a portion of the total cDNA was amplified by PGR using 94°C
dénaturation,

55°G

annealing

and

72°C

extension temperatures, for 27

cycles with the first four cycles having extended times. Positive and negative
strand primers used for the amplification of each mRNA species were as follows;
G3PDH,

GGAGGGAAAGGGGTGATGATGTC

ATGGGTGTTGACGAGGTTGTTG;

IL-6, AGAGTTGTGGAATGGGAATTC

and
and

GGTTGTGTGAGTGTAAGTTGTGGA. Amplified products were electrophoresed
on ethidium bromide stained gels and visualized under UV illumination. Analysis
of cDNA samples were corrected for expression of G3PDH.
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SDS-PAGE Western blot analysis
Protein lysates were separated on a SDS-PAGE gel. Poly- acrylamide gels
were purchased precasted (Pierce). The gels were subsequently transferred to a
Hotter SE 250 Minivertical Gel Electrophoresis Unit (Amersham) filled with TrisHEPES (0.1 M HEPES, 0.1 M Tris, 0.1% w/v SDS) running buffer. Equal
amounts of protein (5 - 25 pg) were loaded into each lane of the precast gel.
Biotinylated and prestained protein ladders were also loaded onto the stacking
gel to determine molecular weight mobility and transfer efficiency, respectively.
The proteins were electrophoretically separated at 4 °C, using a constant voltage
of 100 V. Following electrophoresis, the proteins were transferred (Hoefer TE22
Mighty Small TransPhor Tank, Amersham) to 0.45 pm nitrocellulose membranes
at 4 °C, using constant amperage of 360 mA, for 90 min in Western transfer
buffer (25 mM Tris, 192 mM Glycine, and 20% v/v methanol, note: pH was not
adjusted).
Following the transfer period, protein-containing membranes were washed
once for 5 minutes in tris-buffered saline containing tween (TBST: 50 mM Tris pH
7.4, 150 mM NaCI, and 0.1% v/v Tween-20) for 5 min. After the washing period
the membranes were blocked with TBST containing 5 % nonfat milk (Nestlé
Carnation) for 1 hour, then washed three times in 5 minutes intervals in TBST.
The membrane was incubated 12 hours with primary antibodies at the dilutions
indicated by manufacturer’s instructions at 4°C. After the antibody incubation
period, the antibody solution was removed and the membranes washed in TBST
three times for 5 minute intervals. Membranes were then incubated with a
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secondary antibody conjugated to a horseradish peroxidase (HRP) and anti
biotin. Both secondary and anti-biotin antibodies were diluted using the
manufactures

recommendation,

of

1:5000

and

1:1000,

respectively.

All

antibodies were diluted in TBST containing 0.1% BSA (Antibody Dilution Buffer).
The incubation period for secondary antibody and anti-biotin of 1 hour,
aften/vards both were removed and washed in TBST three times for 5 minute
intervals.

Proteins were visualized on the Typhoon multipurpose imager using

the ECL-plus® detection reagent according to the manufacturer’s specifications
(Amersham).
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CHAPTER 3

RESULTS
Time dependent release of IL-6 induced byTNF-a and IL-1p
We characterized the effect of TNF-a and IL-1P on IL-6 release in a time
dependent manner using an ELISA format. For groups treated with both
cytokines we determined that at 4 hours no detectable amounts of IL-6 were
release. Furthermore, we observed a time dependent release of IL-6 starting
from 6-12 hours with an even greater amount of IL-6 release occurring at
24hours. (Figure 5).

GABA inhibition of the synergistic release of IL-6 induced
by TNF-a and IL-1|3
We characterized the effect GABA on TNF-a and IL-ip induced IL-6 release
in a time dependent manner using an ELISA format. For groups treated with both
cytokines we observed a time dependent release of IL-6 starting from 6 hours
onward. Furthermore, we observed that GABA inhibits the release of IL-6 at all
time points. (Figure 6).
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Effects of GABA, muscimol, baclofen, TNF-a and IL-1(3
on IL-6 release.
We have previously reported that GABA can inhibit the release of IL-6
induced by IL-1 (3 treatment (Spangelo et al., 2004) using the 7TD-1 bioassay. We
decided to re-explore these observations using an ELISA format to examine the
effects of GABA, muscimol, baclofen, TNF-a and IL-ip on IL-6 Release (Figure
7). In addition GABA, muscimol and baclofen were able to inhibit IL-6 release
caused by the synergistic stimulation of both TNF-a and IL-1 p combined.

TNF-a and IL-ip Effects on p38, kB -a and kB-p
in an extended time course
In order to determine how TNF-a and IL-ip synergy occurs it was necessary
to characterize the effects of TNF-a and IL-ip on p38, kB -a and kB-p. In the
case of p38 we see that the combination of both cytokines caused the activation
of p38 at 5 minutes with maximum activation occurring at 15 minutes followed by
a return to basal activity at 30 minutes (Figure 8). In the case of the NF-kB
inhibitors kB -a and kB-p we observe kB -a degradation at 5 minutes with
maximum degradation at 15 minutes and a return to basal levels after
approximately 30 minutes (Figure 8). As for kB-p we observed no degradation
for any treatments or time points.

22

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Effects of split number on cellular responses
During our research we observed that stimulation agents had dissimilar
effects on cells from different split numbers. We determined that the older cells
which were split in excess of 38 times became less responsive to treatments
than that of the newer lower split numbers. We have established that TNF-a and
IL-ip have an effect on Ik B-o degradation as early as 5 minutes followed by
maximum degradation at 15 minutes. Experiments carried out together involving
cells of a higher split number and lower split demonstrated that the higher split
becomes less responsive at 5 and 15 minutes than that of the lower split (Figure

9 ).

Effects of TNF-a and IL-ip on p38, kB -a and kB-p
at 2-10 minutes
During our studies we hypothesized that the release of IL-6 induced by both
cytokines in combination may be a result of an enhanced effect on p38 activation
or kB-a degradation. We first investigated two time points at 2 and 5 minutes
and did not observe any enhanced effect on p38 activation or kB -a degradation
at 2 minutes (Figure 10). At 5 minutes both cytokines combined appeared to
have a stronger effect on kB -a degradation than either single cytokine
treatments alone. Additional time points at 7.5 and 10 minutes were further
analyzed (Figure 11). At 7.5 minutes there is more kB -a degradation when
treated with both cytokines and at 10 minutes we see considerably more
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degradation of Ik B-o when treated with both cytokines. There appeared to be no
enhanced effect on p38 activation at any time points.

Effects of muscimol, baclofen, TNF-a and IL-1P
on p38, Ik B-o and kB-p
With the effects of muscimol, baclofen, TNF-a and IL-ip on IL-6 characterized
in an ELISA format we then explored the effects each had on p38, kB -a and kB P using Western blots (Figure 12). At the maximum doses of 100 ng/mL for TNFa and 50 ng/mL IL-ip we observed activation of p38 and degradation of kB -a
but not kB-p when treated with cytokines alone or in combination. In addition,
muscimol and baclofen did not reverse the effects of the cytokines when used in
combination.

Effects of TNF-a, IL-ip, BAY 11-7082 and GABA
on kB -a degradation
We determined the effects TNF-a, IL-ip, Bay 11-7082 and GABA on kB -a
degradation via Western blot. Bay 11-7082 (Figure 13) is an inhibitor of NF-kB
and prevents the phosphorylation of inhibitory protein inhibitor-xB-p (kB-P)
bound to NF-kB (Ohkita et al., 2002), in addition it can also inhibit kB-p
expression (Lappas et al., 2005). We observed a considerable increase in
degradation kB -a when cells were treated with 100 ng/mL TNF-a, 50 ng/mL ILip alone and with both cytokines combined (Figure 14) which was reversed by
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Bay 11-7082. In addition the inhibitory peptide GABA had no effect in reversing
this degradation.

Effects of low concentrations of TNF-a and IL-1 p
on p38, IkB-o and kB-p
We previously characterized the effects TNF-a and IL-ip have on p38, kB -a
and kB-p (data not shown). Although both cytokines are effective at higher
concentrations it was necessary to characterize the effects of these cytokines at
lower concentrations to determine a minimum effective concentration. We first
analyzed 1 ng/mL TNF-a at three different concentrations of IL-ip that included
0.5,1 and 5 ng/mL. For the TNF-a treatment alone we observed little or no effect
on p38 activation and virtually no effect on kB -a or kB-p degradation (Figure
15). W e observed little or no effect on p38 activation, kB -a or kB-p degradation
when treated with IL-ip at 0.5 ng/mL. At 1 ng/mL we observed a weak activation
of p38 when compared to the 0.5 ng/mL treatment and an increased activation
when treated with 5 ng/mL of both cytokines. This p38 activation coincided with a
strong degradation of kB-a. In addition there was no effect on kB-p degradation
for any treatment groups.

Effects of low concentrations of TNF-a, IL-1 P and GABA
on kB -a and kB-p
With the effects of low concentrations cytokines characterized we opted to
increase these concentrations of TNF-a and IL-ip in an attempt to clarify a more
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observable effect on IkB-q and kB-p, for this we used concentrations of 2, 5 and
10 ng/mL for both TNF-a and IL-ip. Consistent with previous findings the co
treatments of both cytokines caused the degradation of the NF-kB Inhibitors kB a but not kB-p. Furthermore, Im M GABA did not reverse this effect (Figure 16).

Effects of TNF-a, IL-1 p and GABA dose responses
on kB -a and kB-p
With low cytokines concentrations characterized we decided to use 2 ng/mL
as our low effective concentration. Furthermore, in conjunction with the cytokine
co-treatments we characterized a GABA dose response ranging in concentration
from 0.01 to 10 mM. As expected, co-treatments of both cytokines caused the
degradation of the NF-kB inhibitors kB -a but not kB-p. In addition contreatments caused the activation of p38 (Figure 17). Furthermore, GABA
treatments did not reverse the effects of the cytokines.

Effects of TNF-a, IL-1 P and GABA on IL-6 transcription
Next, we evaluated the effects of TNF-a,

IL-ip and GABA on IL-6

transcription. TNF-a and IL-ip caused an increase in IL-6 transcription (Figure

18), in addition both cytokines combined induced a large increase in IL-6
transcription. Interestingly, when cytokines and GABA are combined, GABA did
not inhibit IL-6 transcription induced by both cytokines. Relative expression levels
were measured verifying visual observations (Figure 19).
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Evaluation of total cellular content of IL-6
We have demonstrated that we can measure IL-6 release through the use of
ELISA. We explored the idea of assaying total cellular IL-6 content via Western
blot. We evaluated three different rabbit anti-rat IL-6 antibodies purchased from
Pierce Biotechnology, Peprotech and Cell Sciences (Figure 20). The antibody
purchased from Cell Sciences demonstrated more specific binding to IL-6
allowing us to better distinguish IL-6. In addition when 25 pg of protein were
loaded into each well the bands were clearly more intense than that of the other
antibodies. With these results further IL-6 Western analysis was done using the
Cell Sciences antibody and based on the intensity of the bands a lower amount
of protein was analyzed. We analyzed 10 pg of protein separated on Western
blot to determine the effects of GABA and cytokines (Figure 21). We observed a
more intense IL-6 band for the TNF-a and IL-ip combined treatment indicating a
large amount of IL-6. This accumulation of IL-6 was reversed with the use of
GABA.
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CHAPTER 4

DISCUSSION
GABA inhibition of the synergistic release
of IL-6 by TNF-a and IL-1P
Our lab has previously established that TNF-a and IL-ip combined induce a
synergistic effect on IL-6 release (data not shown). To evaluate the roles of
GABA and agonists on IL-6 release, it was necessary to characterize IL-6
release induced by these two cytokines in a time dependent manner (Figure 5).
After 4 hours of treatment no detectable amounts of IL-6 was released.
Detectable levels of IL-6 occurred at approximately 6 hours, continuing after 8
hours with maximum accumulation of IL-6 after 24 hours.
We have previously reported that GABA can inhibit the release of IL-6
induced by IL-1P treatment (Spangelo et al., 2004) using the 7TD-1 bioassay.
These observations were re-explored in an ELISA format from 6-12 hours

(Figure 6). We found that GABA can inhibit IL-6 release at all time points
supporting our previous findings. W e then examined the effects of GABA
muscimol, baclofen TNF-a and IL-ip on IL-6 release and found that GABA,
muscimol and baclofen were all able to inhibit the synergistic stimulation of IL-6
release induced by TNF-a and IL-ip (Figure 7). This preliminary data suggests
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that GABA inhibition of IL-6 can use either GABA receptor subtypes for signaling.
We determined through a literature search that 100 pM of baclofen is the
standard concentration used, whereas we used 500 pM. We will reevaluate these
results using the recommended dose of 100 pM baclofen and we predict that
GABA and muscimol but not baclofen will inhibit IL-6 release caused by Tl
synergy.

Mechanism of the TNF-a and IL-ip synergistic stimulation
of IL-6 release
Our first hypothesis states that the synergistic effect of TNF-a and IL-ip on
IL-6 release is caused by an increase in IL-6 transcription. In order to test this we
felt it was necessary to first characterize the kinetics of TNF-a and IL-ip on p38
activation and Ik B degradation. We see that both cytokines used together
activated p38 at approximately 5 minutes reaching maximum activation at 15
minutes followed by a return to basal activity after 30 minutes (Figure 8).
Coincidentally

there

is

considerable

degradation

in

kB -a

starting

at

approximately 5 minutes with maximum degradation occurring at 15 minutes and
a return to basal activity at 30 minutes. Consistent with previous experiments we
observed no changes in kB -p degradation.
During our research we observed that stimulatory agents were having
dissimilar effects on cell lines of different split numbers. It appeared that the
higher split numbers starting at approximately 38 become less responsive to our
treatments. We tested this observation on the two different split lines with
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cytokines alone and in combination and we determined that the high split
numbers become less responsive. We have established that cytokine treatments
induce Ik B-o degradation as early as 5 minutes followed by maximum
degradation at 15 minutes. Experiments carried out together involving the two
different split numbers demonstrated that the higher split number did not respond
to our treatments at either 5 or 15 minutes (Figure 9). From these observations
we determined that cell cultures of approximately 38 splits were to be discarded
and fresh cell cultures grown to replace them. After these observations all
subsequent experiments were done with cell splits of 5-35.
In regards to the previous kinetics study we postulated that the synergistic
effect of IL-6 transcription and subsequent release may be a result of an
accelerated effect on p38 activation and/or N F- k B activation. We

have

established that p38 activation and Ik B-o degradation occur as early as 5
minutes when cytokines are used alone. We predicted that if there is an
accelerated effect when both cytokines are used together we would observe
activation of p38 or Ik B-o degradation at earlier time points or a stronger
activation. We decided the first time points to be examined would be 2 and 5
minutes (Figure 10). For the 2 minute time point we did not observe any effect
on p38 activation or Ik B-q degradation. However, when both cytokines are
combined there appears to be a increase in p38 activation and Ik B- o degradation
at 5 minutes when compared to cytokines alone. From this observation we then
decided to analyze the effects of both cytokines at further time points of 7.5 and
10 minutes (Figure 11). Consistent with our previous findings, groups treated
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with cytokines alone had an increase in activated p38 and Ik B-o degradation.
When compared to groups treated with both cytokines, we observed a stronger
activation of p38 and degradation of Ik B-o for all time points. From this data
presented we propose that the synergistic induction of IL-6 release caused by the
combined effects of TNF-a and IL-1P is a result of an accelerated effect on p38
and N F - k B activation.

Effects of GABA on the inhibition of IL-6 release induced
by TNF-a and IL-1P
With guidance from our ELISA data we then explored the effects of each
cytokines alone, together and in combination with muscimol or baclofen. This
was done to determine how each affected p38 activation, Ik B-o and Ik B-P
degradation in an attempt to determine if the signaling goes through one of these
modes. At the maximum doses of 100 ng/mL for TNF-a and 50 ng/mL IL-ip we
observed activation of p38 and degradation of Ik B-o but not kB-p when treated
with cytokines alone or in combination (F ig u re 12). In addition, muscimol and
baclofen did not reverse the effects of the cytokines when used in combination.
Our previous findings have shown that Bay 11-7082 can inhibit the
synergistically stimulated release of IL-6 (data not shown). With this in mind we
used this N F - k B inhibitor as a positive control for GABA. We observed a
considerable increase in degradation kB -a when 100 ng/mL TNF-a, 50 ng/mL
IL-ip and with both cytokines combined (F ig u re 14).

In addition the N F - k B

inhibitor Bay 11-7082 effectively inhibited the degradation of kB -a but GABA had
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no effect in reversing this degradation. From our ELISA data and Western data
we concluded that GABA, muscimol and baclofen had no inhibitory effect on p38
activation or Ik B degradation.
Using maximum doses of cytokines, GABA and agonists resulted in no
observable effects on p38 activation and Ik B degradation. W e postulated that the
effects of GABA and agonists may be subtle and thus masked by a high effective
concentration of both cytokines. Therefore, we designed a series of experiments
to determine the minimum effective concentration of these cytokines that induces
a minimal response to p38 activation and Ik B degradation. Once a concentration
of minimal effect was determined we would then use cytokines at this low
concentration treat and co-treat with the maximal dose of GABA in an attempt to
induce a stronger response from GABA that should not be masked by the
cytokines at minimal doses.
To determine the minimal effective dose we started at 1 ng/mL TNF-a and
compared this to three different doses of IL-13 that included 0.5, 1 and 5 ng/mL

(Figure 15). For the TNF-a treatments we observed little or no effect on p38
activation and virtually no effect on kB -a or kB-p degradation. Treatment with
IL-ip of 0.5 ng/mL the effects were similar to TNF-a and there was little effect on
p38 activation and no degradation on either kB. At 1 ng/mL we observed a
stronger activation of p38 when compared to the 0.5 ng/mL and no degradation
in kB -a and no change in kB-p. When treated 5 ng/mL IL-ip we observed
stronger activation of p38 and degradation of kB -a than those compared to the
other doses and 1 ng/mL TNF-a. When combined with 1 ng/mL TNF-a we find
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that TNF-a and 0.5 ng/ mL IL-ip had little or no effect on p38 activation and
virtually no effect on degradation on either IkB. When treated with 1 ng/mL TNFa and 1 ng/mL IL-ip we find a weak activation of p38 and some degradation in
Ik B-o and this effect is even more obvious when 1 ng/mL TNF-a is combined with
5 ng/mL IL-1 p.
With a minimum effective dose determined for both cytokines we decided to
further explore the effects of minimal concentrations. We decided to analyze the
effects of equal amounts of cytokines and analyzed the effects of 2, 5 and 10
ng/mL (Figure 16). For these treatments we observed degradation of kB -a but
no change in kB-p degradation. However, the effects were weaker for the 2 and
5 ng/mL treatment groups when compared to the 10 ng/mL group. From these
results we decided to use 2 ng/mL concentrations combined with GABA. The
concentrations of GABA for this treatment included 0.01, 0.1, 1 and 10 mM. We
observed no effect in p38 activation or kB-p degradation from any treatment
groups for cytokines alone or in combination with GABA (Figure 17). With these
results it has been demonstrated that GABA did not inhibit p38 activation or kB -a
degradation at both low and high doses. All the results presented to this point
effectively refuted our second hypothesis that GABA may have an effect on p38
and NF-kB activation.
With one hypothesis refuted we then analyzed the effects of IL-6 transcription
which is the basis of our other two hypotheses. We observed that treatment with
100 ng/mL TNF-a or 50 ng/mL IL-ip resulted in increase of IL-6 transcription

(Figure 18 and 19). When both cytokines used in combination a massive
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induction of IL-6 occurs, this induction was not simply an additive effect of either
cytokine but several times greater (synergistic). This result provides evidence
that supports our first hypothesis that states the synergistic effect of TNF-a and
IL-ip may act on IL-6 transcription. We have demonstrated that when both
cytokines are used in combination there is an accelerated effect on p38
activation and kB -a degradation. Combined with this result we propose that this
synergistic effect is a result of the combined cytokines having accelerated effects
on p38 activation and NF-k B activation ultimately resulting in an accelerated
increase in IL-6 transcription. Furthermore, we hypothesized that GABA may
inhibit this synergistic effect by inhibiting IL-6 transcription. If true, we predict that
we would see a decrease in IL-6 transcripts when treated with GABA. However,
we observed that GABA did not inhibit IL-6 transcription caused by both
cytokines combined. This is in opposition to our prediction and suggests that
GABA contributes to an increase of IL-6 or even stabilizes the transcript. We
argue that there is an accumulation in IL-6 transcript in the GABA treated groups
because GABA may prevent the translation of IL-6.
From the mRNA data we hypothesized that GABA may be preventing the
translation of IL-6. With this in mind we predicted that if GABA prevents IL-6
translation we will see a decrease in IL-6 content in GABA treated groups when
analyzed via Western blot.

In order to test this we first had to determine if a

Western format is feasible for IL-6 analysis. For this experiment C6 cells were
plated, no stimulation agents were used and protein extracted (Figure 20). We
analyzed these blots with an anti-rat IL-6 antibody (1:1000 dilution) purchased
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from Pierce Biotechnology, Peprotech and Cell Sciences. For all antibodies we
were able to detect IL-6 and also observed non-specific binding at other weight
ranges. The antibodies purchased from Pierce and Peprotech were very similar,
the antibody purchased from Cell Sciences gave us the best results. We
determined an effective detection by two categories [a] a limit on non-specific
binding and [b] the intensity of the bands/signal at the 28 kDa range where
functional IL-6 should be isolated. With the Cell Sciences antibody there was
more specific binding and a stronger signal detected at the 28 kDa range. Also
we concluded that the band was too intense and may be indicative of protein
overloading. Therefore for future IL-6 Westerns we lowered the amount of protein
to load from 25 pg to 10 pg. With these results we concluded that it is possible to
measure IL-6 effectively in a Western format and that the Cell Sciences antibody
proved to be the ideal reagent.
We then analyzed the effect of GABA and cytokines on IL-6 content (Figure

21). We observed a large accumulation of IL-6 for the TNF-a and IL-ip combined
treatments and when these two were combined with GABA less IL-6 was
detected. This result combined with the mRNA data suggests that GABA
inhibition of IL-6 release may act through the prevention of IL-6 translation. This
possibility will be explored in future endeavors by our lab. From these results we
ruled out our third hypothesis that GABA inhibits IL-6 transcription but determined
that GABA appears to inhibit IL-6 translation. With the information gathered for
this thesis we have proposed a potential GABA inhibitory pathway shown in

Figure 22.
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A potential model for GABA inhibition of IL-6 translation may be through the
activation of 4E-BP1 also known as PHAS 1. In eukaryotes, mRNA posses a 5’
“cap” structure which is recognized by the cap binding protein elF4E allowing the
first step in ribosome scanning (Martin et al., 2000). Different stimuli can cause
the phosphorylation of elF4E, which activates this initiation factor resulting in an
increase in protein synthesis (Sonenberg 1996). In addition the activation of
elF4E enhances its affinity to bind to mRNA (Minich et al., 1994). 4E-BP1 is a
cytoplasmic inhibitor which maintains elF4E in an inactive form (Martin et al.,
2000). Phosphorylation of 4E-BP1 causes it to release elF4E allowing the proper
formation of a functional elF4E complex that allows efficient binging and proper
positioning of the 40 S ribosomal subunit on mRNA (Lawrence and Abraham
1997).
GABA may be preventing 4E-BP1 from releasing elF4E, preventing the
ribosomal complex from forming in turn inhibiting translation. Interestingly, a
functional assay for 4E-BP-elF4E binding was developed by Gingras and
colleagues from which we could test the effects of GABA. Using this method we
predict that TNF-a and IL-ip combined treatments will result in the dissociation of
4E-BP-elF4E complex which will be inhibited by GABA.
Polysome fractionation is another potential method to assay for translational
inhibition in a method similar to that described by Koritzinsky and colleagues.
This method involves the separation of cell lysates on sucrose gradients then
RNA levels are measured as a function of gradient depth. Efficient translation of
mRNA requires the association with many ribosomes (polysomes) and therefore
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would sediment deep in the sucrose gradients (Koritzinsky et al., 2005). We
hypothesize that GABA may inhibit translation by preventing the formation of the
polysomes. We predict that TNF-a and IL-1P combined treatments will result in
polysomal bands deep in the sucrose gradients. Furthermore, we predict that this
banding deep in the sucrose gradient will not be present in the GABA treated
groups.
In summary, from the results presented in this thesis we have evidence
suggesting that the synergistic effect of TNF-a and IL-ip is a result of an
enhanced effect on p38 and NF-k B activation resulting in enhanced IL-6
transcription. Furthermore, GABA may prevent IL-6 translation based on the
following three observations, [a] GABA did not prevent the activation of p38 and
or NF-k B, [b] GABA did not reduce the transcription of IL-6 and [c] GABA treated
groups had less total cellular IL-6. From this data we postulate that this decrease
of IL-6 protein is a result of GABA inhibiting translation possibly by blocking IL-6
transcript release from the nucleus or by inhibiting translation directly.
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Figure 1: Representation demonstrating that neuroinflammation and beta
amyloid synergy is essential to AD progression
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Figure 2: Structural projection for the inhibitory neurotransmitter GABA.
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Figure 3: Structural projections of GABA receptor agonists. Muscimol acts on
GABAa receptors and baclofen on GABAb receptors.
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Figure 4: GABA inhibition of the synergistic release of IL-6 by IL-1p and TNFa. Rat C6 cells were plated (1.0 x 10® cells/well in a PDL-coated 24-well
plate) and were pretreated with 1 mM GABA for 1 hour and co-treated with 1
mM GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post
stimulation, conditioned medium was removed and assayed for IL-6 using
Pierce ELISA according to the manufacturer’s specifications. A (+) indicates
C6 glioma cells were treated as; con = no stimulation agents T = TNF-a, I =
IL-ip, G = GABA. Data presented in this figure is a confirmation of previous
unpublished results. The data are presented as mean ± s.e.m. of triplicates
observations obtained from a single representative experiment.
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Figure 5: Time dependent release of IL-6 by IL-ip and TNF-a. Rat C6 cells
were plated (1.0x10® cells/well in a PDL-coated 24-well plate) treated with 50
ng/mL IL-ip and 100 ng/mL TNF-a alone or in combination for 4, 6 , 8 , 1 2 and
24 hours. Post stimulation, conditioned medium was removed and assayed
for IL-6 using Pierce ELISA according to the manufacturer’s specifications.
C6 glioma cells were treated as; C = no stimulation agents Tl = TNF-a and IL1 combined with times indicated by hrs = hours. The data are presented as
mean ± s.e.m. of triplicates observations obtained from a single
representative experiment.
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Figure 6: GABA inhibition of the synergistic release of IL-6 by IL-ip and TNF-a.
Rat C6 cells were plated (125 x 10® cells/well in a PDL-coated 96-well plate) and
were pretreated with 1 mM GABA alone for 1 hour and co-treated with 50 ng/mL
IL-ip and 100 ng/mL TNF-a for 4-12 hours. Post stimulation, conditioned
medium was removed and assayed for IL-6 using Pierce ELISA according to the
manufacturer’s specifications. T = TNF-a, I = IL-ip and G = GABA. The data are
presented as mean ± s.e.m. of triplicate observations obtained from a single
representative experiment.
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Figure 7: GABA inhibition of the synergistic release of IL-6 by IL-ip and TNFa. Rat 0 6 cells were plated (125 x 10® cells/well in a PDL-coated 96-well
plate) and were pretreated with inhibitors (1 mM GABA, 100 |iM muscimol
and 500 pM baclofen) alone for 1 hour and co-treated with inhibitors alone, 50
ng/mL IL-ip and 100 ng/mL TNF-a for 20 hours. Post stimulation, conditioned
medium was removed and assayed for IL-6 using Pierce ELISA according to
the manufacturer’s specifications. T = TNF-a, I = IL-ip, G = GABA, M =
muscimol and B = baclofen. The data are presented as mean ± s.e.m. of
triplicate observations obtained from a single representative experiment.
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Figure 8: The extended time course and effects of TNF-a and IL-1P on p38
activation and degradation of IxB-a and IxB-p. Rat C6 cells (3x10® cells/dish
in a 35 X 10 mm-dish) were treated 50 ng/mL IL-ip and 100 ng/mL TNF-a for
0, 5, 15, 30, 45, 60, 90 and 120 minutes. Post stimulation, cellular protein
was extracted, and 25 pg of total protein were subsequently separated via
SDS-PAGE followed by Western analysis for IxB-a, IkB-P, phosphorylated or
total p38 protein (1:1000 for all). The data are presented as the observations
obtained from a single experiment.
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Figure 9: The effects of TNF-a and IL-ip degradation of k B -a and Ik B-P for
high and low cell splits. Rat C6 cells (3x10® cells/dish in a 35 x 10 mm-dish)
were treated 50 ng/mL IL-ip and 100 ng/mL TNF-a for 0, 5, 15, 30, 45, 60, 90
and 120 minutes. Post-stimulation, cellular protein was extracted, and 25 pg
of total protein were subsequently separated via SDS-PAGE followed by
Western analysis for kB -a, kB-p, phosphorylated or total p38 protein (1:1000
for all). The data are presented as the observations obtained from a single
experiment.
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Figure 10: The effects of TNF-a and IL-ip on p38 activation and degradation
of k B -a and kB-p at 2 and 5 minute time points. Rat C6 cells (3 x 10®
cells/dish in a 35 x 10 mm-dish) were treated 50 ng/mL IL-ip and 100 ng/mL
TNF-a for 2 and 5 minutes. Post stimulation, cellular protein was extracted,
and 25 pg of total protein were subsequently separated via SDS-PAGE
followed by Western analysis for kB -a, kB-p, phosphorylated or total p38
protein (1:1000 for all). The data are presented as the observations obtained
from a single experiment.
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Figure 11: The effects of TNF-a and IL-ip on p38 activation and degradation
of k B -a and kB-p at 5, 7.5 and 10 minute time points. Rat C6 cells (3x10®
cells/dish in a 35 x 10 mm-dish) were treated 50 ng/mL IL-ip and 100 ng/mL
TNF-a for 5, 7.5 and 10 minutes. Post stimulation, cellular protein was
extracted, and 25 pg of total protein were subsequently separated via SDSPAGE followed by Western analysis for kB -a, kB-p, phosphorylated or total
p38 protein (1:1000 for all). The data are presented as the observations
obtained from a single experiment.
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Figure 12: The effects of muscimol and baclofen on p38, k B -a and kB-p.
Rat C6 cells ( 3 x10® cells/dish in a 35 x 10 mm-dish) were pre-treated with
100 pM muscimol or 100 pM baclofen for 1 hour, and co-treated with either
100 pM muscimol or 100 pM baclofen, 50 ng/mL IL-ip and 100 ng/mL TNF-a
for 15 min. Post stimulation, cellular protein was extracted, and 25 pg of total
protein were subsequently separated via SDS-PAGE followed by Western
analysis for kB -a, kB-p, phosphorylated or total p38 protein (1:1000 for all).
The data are presented as the observations obtained from a single
experiment.
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Figure 13: Structural projections of BAY 11-7082 which inhibits NF-kappaB by
preventing the phosphorylation of kB -p bound to NF-k B.
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Figure 14: The effect of Bay 11-7082 on the degradation of kB -a. Rat C6
cells ( 3 x 1 0 ® cells/dish in a 35 x 10 mm-dish) were pre-treated with 25 pM
Bay 11-7082 for 1 hour, and co-treated with 25 pM Bay 11-7082, 50 ng/mL ILip and 100 ng/mL TNF-a for 15 min. Post stimulation, cellular protein was
extracted, and 25 pg of total protein were subsequently separated via SDSPAGE followed by Western analysis for kB protein (1:1000). The data are
presented as the observations obtained from a single experiment.
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Figure 15: The effects of low concentrations on cytokine on p38 activation
and the degradation of k B -a and kB-p. Rat C6 cells (3x10® cells/dish in a
35 X 10 mm-dish) were treated 0.5, 1 and 5 ng/mL IL-ip and Ing/mL TNF-a
for 15 min. Post stimulation, cellular protein was extracted, and 25 pg of total
protein were subsequently separated via SDS-PAGE followed by Western
analysis for kB -a, kB-p, phosphorylated or total p38 protein (1:1000 for all).
The data are presented as the observations obtained from a single
experiment.
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Figure 16: The effects of low concentrations of cytokine on p38 activation and
the degradation of k B -a and kB-p. Rat C6 cells (3x10® cells/dish in a 35 x
10 mm-dish) were treated 2, 5 and 10 ng/mL IL-ip and TNF-a for 15 min.
Post stimulation, cellular protein was extracted, and 25 pg of total protein
were subsequently separated via SDS-PAGE followed by Western analysis
for k B -a and k B (1:1000 for both). The data are presented as the
observations obtained from a single experiment.
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Figure 17: The effects of low concentrations of cytokine and GABA on p38
activation and the degradation of k B -a and kB-p. Rat 0 6 cells (3 x 10®
cells/dish in a 35 x 10 mm-dish) were pre-treated with 0.01, 0.1, 1 and 10 mM
GABA for 1 hour, and co-treated with either 0.01, 0.1, 1 and 10 mM GABA, 2
ng/mL IL-ip and 2 ng/mL TNF-a for 15 min. Post stimulation, cellular protein
was extracted, and 25 pg of total protein were subsequently separated via
SDS-PAGE followed by Western analysis for kB -a, kB-p, phosphorylated or
total p38 protein (1:1000 for all). The data are presented as the observations
obtained from a single experiment.
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Figure 18: Relative expression of IL-6 transcript in cells treated with GABA,
TNF-a and IL-ip. Rat C6 cells ( 3x10® cells/dish in a 35 x 10 mm-dish) were
pre-treated with 1 mM GABA for 1 hour, and co-treated with either 1 mM
GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 4 hours. Post stimulation,
cellular RNA was extracted, and 1 pg of total RNA extract were subsequently
separated and analyzed via semi-quantitative RT-PCR. The data are
presented as the observations obtained from a single experiment.
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Figure 19: Relative expression of IL-6 transcript in cells treated with GABA,
TNF-a and IL-1|3. Rat C6 cells (3x10® cells/dish in a 35 x 10 mm-dish) were
pre-treated with 1 mM GABA for 1 hour, and co-treated with either 1 mM
GABA, 50 ng/mL IL-ip and 100 ng/mL TNF-a for 4 hours. Post stimulation,
cellular RNA was extracted, and 1 |ig of total RNA extract were subsequently
separated and analyzed via semi-quantitative RT-PCR for IL-6 transcript
relative expression levels determined. The data are presented as the
observations obtained from four experiments.
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Figure 20: Relative effectiveness of IL-6 antibody from Pierce Biotechnology,
Peprotech and Cell Sciences. Rat C6 cells ( 3 x 1 0 ® cells/dish in a 35 x 10
mm-dish). Cellular protein was extracted, and 25 pg of total protein were
subsequently separated via SDS-PAGE followed by Western analysis using
antibodies from each manufacturer (1:1000 for all). The data are presented as
the observations obtained from a single experiment.
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Figure 21: IL-6 content of TNF-a and IL-ip on p38 activation and degradation
of lK0-a and kB-p. Rat C6 cells (3 x 10® cells/dish in a 35 x 10 mm-dish)
were treated 50 ng/mL IL-ip, 100 ng/mL TNF-a and 1 mM GABA alone or in
combination 4 hours. Post stimulation, cellular protein was extracted, and 25
pg of total protein were subsequently separated via SDS-PAGE followed by
Western analysis for kB -a, kB-p, phosphorylated or total p38 protein (1:1000
for all). The data are presented as the observations obtained from a single
experiment.
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Figure 22: Proposed mechanism of GABA inhibition of IL-6 release caused by
the synergistic induction of TNF-a and IL-ip.
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